Search results
Federal Circuit Upholds Rifaximin Patent Rulings, Affirms ANDA Approval Restrictions
The National Law Review· 3 days agoIn Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc. 2023-1952 (Fed. Cir. April 11,...
Starbucks files multiple patents in Russia
Verdict Food Service via Yahoo Finance· 5 days agoPrior to its exit, Starbucks employed 2,000 individuals across 130 stores in Russia. Its premises were operated by Alshaya Group. "Starbucks files...
The 5 Stocks Defining 'The Year Of The Dividend' In 2024
Benzinga via Yahoo Finance· 7 days agoReinvested stock dividends have significantly influenced the total return of the S&P 500 since 1927....
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
Zacks via Yahoo Finance· 4 days agoHalozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of...
JD Supra: Federal Circuit Review
JD Supra· 10 hours agoIn Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals Usa, Inc., Appeal No. 22-1258, the Federal Circuit held that district court erred by adding unclaimed limitations to the claims in analyzing ...
2 High-Yield Dividend Stocks to Buy Right Now | The Motley Fool
The Motley Fool· 5 days agoDividend stocks are sensitive to interest rates. When rates fall, studies show that money managers...
Cross This Bridge With a Potentially Big Upcoming Catalyst
TheStreet.com· 15 hours agoHere's why this midcap biotech name makes for a solid covered call trade. The company is $5 billion...
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
StreetInsider· 4 days agoConference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET SAN...
Halozyme stock hits 52-week on guidance raise (NASDAQ:HALO)
Seeking Alpha· 4 days agoHalozyme Therapeutics (HALO) stock gains as company raises full-year outlook after securing a new...
3 Dow Stocks That Are No-Brainer Buys in June
Motley Fool via Yahoo Finance· 3 days agoDevoting capital to internal drug development and collaborations, and constantly refreshing its pipeline, has helped J&J's pharmaceutical segment avoid...
